Comments
Suven Life Sciences has secured a product patent each from India and South Korea for treatment of disorders associated with neuro-degenerative diseases. The patents are valid through 2029 and 2033, respectively, the company said in a BSE filing.
“We are pleased by the grant of these patents to Suven for our pipeline of molecules in CNS (central nervous system) arena, that are being developed for cognitive disorders with high unmet medical need with a huge market potential globally,” Suven Life CEO Venkat Jasti said.
Suven Life said the granted claims of the patents are being developed as therapeutic agents and are useful in the treatment of cognitive impairment associated with neuro-degenerative disorders like Alzheimer’s disease, Parkinson and Schizophrenia.
Suven shares were trading 2.28 per cent higher at Rs 195.55 on the BSE.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.